ArticleTurkish journal of medical sciences2026
Sarcopenia risk in women with postmenopausal osteoporosis: a SARC-F-based assessment.
Article in Turkish journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Osteoporosis and sarcopenia are diseases of bone and muscle tissue, respectively. Studies reported that these disorders were interrelated. However, this relation was explored in older adults and/or with certain comorbidities, and information about nonelderly postmenopausal women is scarce. This study's objectives were to investigate the relationship between osteoporosis and SARC-F-defined sarcopenia risk in postmenopausal women aged ≤70 years and to examine the effect of other factors on this risk. Materials and methods: This multicenter case-control study included postmenopausal women aged 45-70 years. Dual-energy X-ray absorptiometry was utilized to diagnose osteoporosis. Sociodemographic and clinical variables, sarcopenia risk (SARC-F), muscle strength (grip strength and five-times sit-to-stand test: 5T-STS), and physical activity levels (International Physical Activity Questionnaire-Short Form) were compared between osteoporotic and nonosteoporotic participants. Results: A total of 119 osteoporotic (median age: 58 years) and 119 nonosteoporotic (median age: 59 years) participants were recruited. No differences were observed between the osteoporotic and nonosteoporotic groups regarding SARC-F-defined sarcopenia risk (48.7% vs. 38.7%, p = 0.117), probable sarcopenia (14.5% vs. 15.3%, p = 0.876), grip strength (23 vs. 22 kg, p = 0.329), 5T-STS (13.90 vs. 13.96 s, p = 0.986), or physical activity levels (907.5 vs. 792 MET-min/week, p = 0.983). Although educational level [odds ratio (OR): 0.366, 95% confidence interval (CI): 0.189-0.707, p = 0.003], proton pump inhibitor (PPI) use (OR: 2.494, 95% CI: 1.227-5.068, p = 0.012), and physical activity level (OR: 0.966, 95% CI: 0.945-0.988, p = 0.003) were independent predictors of SARC-F-defined sarcopenia risk, osteoporosis was not (p = 0.176). Conclusion: SARC-F-defined sarcopenia risk was not increased in women with postmenopausal osteoporosis aged ≤70 years compared to nonosteoporotic controls. Lower educational status, PPI use, and low physical activity levels were associated with an increased SARC-F-defined sarcopenia risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.